Hib-TT
Phase 2Biologic
NovartisHib-TT is one of 13 biologic programs targeting Typhoid Fever. It is currently in Phase 2.
1
Indications
2
Total Trials
0
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
24 competitors in Typhoid Fever
#DrugCompanyPhaseTrials
1Merrem
BB. Braun Medical Inc.
Approved
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Rocephin
CConrado Roberto Hoffmann Filho
Approved
Hepatitis a Vaccine
SanofiApproved
Cipro
BayerPhase 2
Oral Cholera Vaccine
TakedaApproved
Levaquin
WWim Janssens
Phase 2
Gsk's Investigational Vaccine 692342
GSKPhase 2
Typhoid Vi Vaccine
IInternational Vaccine Institute
Approved
TYPHIBEV
GSKPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Typhoid Fever1 trial
Safety, Immunogenicity and Compatibility With DTP of a Typhoid Fever Vaccine in Infants
Completed·EEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·Phase 2·NCT00342628·301 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Hib-TT. EMBL-EBI & Wellcome Sanger Institute.
- [4]